source
- AstraZeneca halts Phase 3 lung cancer trial of bispecific antibody volrustomig after interim data miss survival goalAstraZeneca announced termination of the Phase 3 study of its experimental bispecific antibody volrustomig in non‑small cell lung cancer. An interim data review by trial monitors indicated the dru…
- Becton Dickinson recalls intraosseous needle sets over risk of obturator removal difficultyBecton Dickinson has issued a recall for specific intraosseous vascular access system needle sets after discovering that the obturator (stylet) can be difficult to remove once the device is placed.…